We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: liver fibrosis
MedXY News
EnglishTag

liver fibrosis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Enhancing Prognostication in Chronic Liver Disease: The Role of Liver Corrected T1 and Magnetic Resonance Elastography in Real-World Clinical Practice
Gastroenterologychronic liver diseaseliver fibrosis

Enhancing Prognostication in Chronic Liver Disease: The Role of Liver Corrected T1 and Magnetic Resonance Elastography in Real-World Clinical Practice

By MedXY|Oct 29, 2025

This study highlights the complementary utility of liver corrected T1 (cT1) and magnetic resonance elastography (MRE) for predicting chronic liver disease progression, emphasizing the critical prognostic role of disease activity beyond fibr

Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis
Gastroenterologyliver fibrosismonoclonal antibodies

Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis

By MedXY|Oct 28, 2025

Claudin-1 is upregulated in primary sclerosing cholangitis (PSC), promoting biliary fibrosis and cholestasis. Preclinical models show that Claudin-1-specific monoclonal antibodies reduce liver injury and fibrosis, highlighting a promising t

Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts
Cardiologyclinical outcomesHypertension

Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts

By MedXY|Oct 28, 2025

Hypertension independently worsens clinical outcomes and liver fibrosis progression in MASLD, highlighting the need for integrated cardiovascular and hepatic care.

Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial
GastroenterologyBexotegrastliver fibrosis

Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial

By MedXY|Oct 28, 2025

The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted th

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis
Diabetes & Endocrinologybiomarkersliver fibrosis

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY|Oct 9, 2025

A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.

Efruxifermin Demonstrates Promising 96-Week Efficacy and Safety in Treating Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase 2b HARMONY Trial
Diabetes & Endocrinologyefruxiferminliver fibrosis

Efruxifermin Demonstrates Promising 96-Week Efficacy and Safety in Treating Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase 2b HARMONY Trial

By MedXY|Oct 5, 2025

The HARMONY trial reveals that once-weekly efruxifermin significantly improves liver fibrosis without worsening MASH over 96 weeks, with a favorable safety profile supporting its phase 3 evaluation.

Intermittent Fasting vs Low-Calorie Diet in Managing Metabolic-Associated Fatty Liver Disease: Comparative Effects on Inflammation, Lipids, Glycemic Control, and Liver Fibrosis
Clinical Updatesintermittent fastingliver fibrosis

Intermittent Fasting vs Low-Calorie Diet in Managing Metabolic-Associated Fatty Liver Disease: Comparative Effects on Inflammation, Lipids, Glycemic Control, and Liver Fibrosis

By MedXY|Oct 5, 2025

This RCT compares 16:8 intermittent fasting and low-calorie diets in MAFLD patients, revealing both improve liver enzymes and anthropometrics, but low-calorie diet shows superior reduction in liver steatosis, fibrosis, and triglycerides.

HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies
Clinical Updatesclinical trialHTD1801

HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies

By MedXY|Oct 4, 2025

HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort
Clinical UpdatesFIB-4liver fibrosis

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

By MedXY|Sep 30, 2025

A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.

Sharp Rise in Advanced Alcohol-Related Liver Disease Despite Stable Drinking Rates: Changing Population Risks Highlighted by US Data
Gastroenterologyalcohol-related liver diseaseepidemiology

Sharp Rise in Advanced Alcohol-Related Liver Disease Despite Stable Drinking Rates: Changing Population Risks Highlighted by US Data

By MedXY|Sep 30, 2025

A twofold rise in advanced liver fibrosis among US heavy drinkers over two decades is linked to increased metabolic syndrome, age, and socioeconomic risk, not higher alcohol intake.

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities